Strides Pharma Sells Singapore Plant for $15M to Reduce Debt and Costs
Strides Pharma Science (Strides) has recently announced a significant development in its strategic restructuring efforts. The company has signed a binding agreement with Rxilient Biohub to sell its manufacturing facility in Singapore for a total of $15 million. The proceeds from this transaction will be allocated towards reducing the company’s debt. This sale also promises …
Strides Pharma Sells Singapore Plant for $15M to Reduce Debt and Costs Read More »